**Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results of a multicenter, randomized, double-blind, placebo-controlled clinical study**

Howard L Sofen, MD[1]; Kurt Gebauer, MBBS, FACD, FACP[2,3,4]; Lynda Spelman, MBBS, FACD[5,6]; Paul S Yamauchi, MD, PhD[1]; Siu-Long Yao, PhD[7]; Mudgal Kothekar, MD, MBBS[8]; Tushar Nishandar, MD[8]; Iris Kopeloff, MD[7]; Michael Crane, PhD[7]; Ranga Gogineni, PhD[7]; Jerry Bagel, MD[9]

[1]David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; [2]Fremantle Dermatology, Fremantle, WA, Australia, [3]Probity Medical Research, Waterloo, ON, Canada; [4]University of Western Australia, Perth, WA, Australia; [5]Veracity Clinical Research, Woolloongabba, Brisbane, QLD, Australia; [6]Probity Medical Research, Brisbane, QLD, Australia; [7]Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; [8]Sun Pharma Advanced Research Company Ltd., Andheri €, Mumbai, India; [9]Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA

**Primary author:** Howard L Sofen

**Credentials:** MD

**Email:** hsofen@ucla.edu

**Institution:** David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

**Address:** 855 Tiverton Dr, Los Angeles, CA 90024

**Objective 1:** To assess the long-term efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis of the scalp from Week 16 to Week 52 of treatment

**Objective 2:** To assess the safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis of the scalp during 52 weeks of treatment

**Background:** Tildrakizumab, an anti–interleukin-23 p19 antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis, was investigated for the treatment of scalp psoriasis in a Phase 3b, randomized, double-blind, placebo-controlled study (NCT03897088). The primary endpoint, Investigator's Global Assessment (IGA) modified 2011 (scalp) response ("clear [0]" or "almost clear [1]" with ≥2-point reduction from baseline) at Week (W)16, was met. Results through W52 are reported.

**Methods:** Patients originally randomized to tildrakizumab 100 mg continued dosing at W16 and every 12 weeks thereafter; patients randomized to placebo switched to receive tildrakizumab 100 mg at W16, W20, W32, and W44. Efficacy assessments included IGA modified 2011 (scalp), Psoriasis Scalp Severity Index (PSSI), scalp surface area (SSA; % affected), scalp Itch-Numeric Rating Scale (Itch-NRS), and Dermatology Life Quality Index (DLQI). Safety was assessed in all treated patients.

**Results:** Of the 44/89 (49.4%) and 54/89 (60.7%) IGA mod 2011 (scalp) and PSSI 90 responders to tildrakizumab at W16, 36/44 (81.8%) and 44/54 (81.5%), respectively, sustained response at W52 (modified intention-to-treat [mITT] population). From W16 to W52 in patients originally randomized to tildrakizumab/placebo (ITT population), mean (standard deviation) scalp Itch-NRS score decreased from 3.4 (2.8)/6.8 (2.8) to 2.3 (2.6)/2.3 (2.6), SSA involvement from 13.5% (22.3%)/48.0% (25.0%) to 6.1% (15.5%)/8.3% (16.0%), PSSI score from 5.9 (9.2)/25.3 (16.3) to 2.9 (6.9)/3.9 (8.3), and DLQI score from 4.8 (5.6)/12.6 (8.3) to 2.9 (4.4)/2.8 (4.4). No new safety signals were detected.

**Conclusion:** Efficacy and safety of tildrakizumab in patients with scalp psoriasis were maintained through W52.

**Acknowledgments**

The study, analyses, and medical writing support were funded by Sun Pharma.

**Disclosures**

**HLS** has served as a clinical investigator for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Janssen, LEO Pharma, Novartis, Sun Pharma, and UCB. **KG** has received grants and/or honoraria as a consultant, investigator, and/or speaker for Abbott, AbbVie, Amgen, Anacor, Boehringer Ingelheim, Celgene Corporation, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Regeneron Pharmaceuticals, Sandoz, Sanofi-Aventis, Schering-Plough, Sun Pharma, UCB, and Wyeth Pharmaceuticals, and has been on an advisory board for AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, and LEO Pharma. **LS** has been a consultant, and/or scientific adviser, and/or investigator, and/or scientific officer, and/or speaker for AbbVie, Akesobio, Alphyn Biologics, Amgen, Anacor, Ascend, Aslan, Astellas Pharma, AstraZeneca, Blaze Bioscience, Boehringer Ingelheim, Botanix, Bristol-Myers Squibb, Celgene Corporation, Connect Biopharmaceuticals Australia, Dermira, Eli Lilly, Evelo Biosciences, Galderma, Genentech, GSK, Hexima, Immunic Therapeutics, Invion, Janssen, Kiniksa Pharmaceuticals, Kobiolab, LEO Pharma, Lipidio Pharma, Mayne Pharma, Medimmune, Merck, Merck-Serono, Novartis, Otsuka, Pfizer, Phosphagenics Limited, Photon MD, Regeneron Pharmaceuticals, Reistone Biopharma, Roche, Samumed, Sanofi/Genzyme, SHR, Sun Pharma ANZ, Trius Therapeutics, UCB, VYNE Therapeutics, and Zai lab. **PSY** has served as a consultant, investigator, and/or speaker for Abbvie, Amgen, Arcutis Biotherapies, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, EPI Health, Incyte, Janssen, LEO Pharma, Novartis, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and UCB. **SLY, MC and RG** are employees of Sun Pharmaceutical Industries, Inc. **IK** is a former employee of Sun Pharmaceutical Industries, Inc. **MK** and **TN** are employees of Sun Pharma Advanced Research Company Ltd. **JB** has received research funds for the Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona LLC, Dermavant Sciences, LTD, Dermira, UCB, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd, Janssen Biotech, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, Sun Pharmaceutical Industries, Inc., Taro Pharmaceutical Industries Ltd, and Ortho Dermatologics; is or has been a consultant for AbbVie, Amgen, Celgene Corporation, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Biotech, Novartis, Sun Pharmaceutical Industries Inc., UCB; and is or has been a speaker for AbbVie, Celgene Corporation, Eli Lilly, Janssen Biotech, and Novartis.